$CHFS $CAPR $GNCA $OCGN Nice gainers on a red market Friday. Resisted decline with market likely because of low exposure to index funds eg XBI and anticipated catalysts pending. Buying here could be risky though as algos is pricing in the positives. Watch next possible runner $ALEC cash rich, P3 started on Friday, P2 result to present on next Tuesday. Most promising candidate for FTD unmet needs so far. investors.alector.com/news-... SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia at the upcoming 2020 Alzheimer’s Association International Conference being held virtually, July 27-31, 2020. Details for the oral presentation: Presentation Title: AL001 Restores CSF PGRN Levels and Normalizes Disease-associated Biomarkers in Individuals with Frontotemporal Dementia
  • 3